Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (1197)	1/5/2002 11:37:58 AM
From: seminole	Read Replies (1) \| Respond to of 1475

They do not have to sell all the shares at one time. I think it is great they have waited until now to start the shelf, instead of last year. They took a chance that the market would improve and that their stock price would improve. I would guess they have a dollar amount as a goal, not a share number. I would hope there is a minimum share price they would except but this price is probably lower than shareholders would like. I would expect to see the share price decrease without reason right before the stock come off the self. The institutions will demand a good price (low) but the stock price will bounce right back after the sale. The institutions will know the shares are about to be sold so you could see an increase in short interest before the sale. (some of the institutions who hold shares now will hedge their shares before the sale of new shares) I hate investment bankers and after this you may hate them too. IMO, you all are doing the right thing by watching the science, so just hold your nose during the stock sale.

To: Torben Noerup Nielsen who wrote (1197)	1/5/2002 1:30:25 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Torben, They will probably sell all the shares that have been allocated. However, I don't expect that to happen anytime in the near future..(month). There is much information and events that will be delivered in the very near future. 1) Initiate MEDI-507 Phase I/II psoriatic arthritis trials 2) Initiate MEDI-507 Phase III psoriasis trials 3) MEDI-507 Phase II psoriasis data 4) Initiate U.S. Phase III TCELL-HDM studies 5) Initiate Phase I/II Allomune lymphoma studies All of these events are schedule in the first half of 2002. The biggest event IMO will be the Phase II psoriasis data and the announcement of Phase III trials. IMO this will get us into the $15.00 range and will be the time for selling the shares. Management would be foolish(IMO) to issue them now...with all this news coming within 6 months. And to the list mentioned above I should add that with the 4th Q release we will get the first actual product revenue sales for the company. That being the European sales for BCELL-HDM and TCELL-HDM. One analyst has projected $700,000 for BCell and $300,000 for TCell and IMO this will bode well for revenue numbers for such a limited time on the market. $1,000,000 in product revenue is just the tip of the iceberg...(:>)